RT Journal Article
SR Electronic
T1 Biological age in UK Biobank: biomarker composition and prediction of mortality, coronary heart disease and hospital admissions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.12.19014720
DO 10.1101/2019.12.12.19014720
A1 Mei Sum Chan
A1 Matthew Arnold
A1 Alison Offer
A1 Imen Hammami
A1 Marion Mafham
A1 Jane Armitage
A1 Rafael Perera
A1 Sarah Parish
YR 2019
UL http://medrxiv.org/content/early/2019/12/15/2019.12.12.19014720.abstract
AB Background Age is the strongest risk factor for most chronic diseases, and yet individuals may age at different rates biologically. A biological age formed from biomarkers may be a stronger risk factor than chronological age and understanding what factors contribute to it could provide insight into new opportunities for disease prevention.Methods and findings Among 480,019 UK Biobank participants aged 40-70 recruited in 2006-2010 and followed up for 6-12 years via linked death registry and secondary care records, a subpopulation of 141,254 (29.4%) non-smoking adults in good health and with no medication use or disease history at baseline were identified. Independent components of 72 biomarkers measured at baseline were characterised by principal component analysis. The Klemera Doubal method (KDM), which derived a weighted sum of biomarker principal components based on the strengths of their linear associations with chronological age, was used to derive sex-specific biological ages in this healthy subpopulation. The proportions of the overall biological and chronological age effects on mortality, coronary heart disease and age-related non-fatal hospital admissions (based on a hospital frailty index) that were explained by biological age were assessed using log-likelihoods of proportional hazards models.Reduced lung function, reduced kidney function, slower reaction time, lower insulin-like-growth factor 1, lower hand grip strength and higher blood pressure were key contributors to biological age (explaining the highest percentages of its variance) in both men and women, while lower albumin, higher sex hormone-binding globulin and lower muscle mass in men, and higher liver enzymes, blood lipids and HbA1c in women were also important. Across both sexes, a 51-principal component biological age explained 66%, 80% and 63% of the age effects on mortality, coronary heart disease and hospital admissions, respectively. Restricting the biological age to the 12-13 key biomarkers corresponding to the 10 most importantly contributing principal components resulted in little change in these proportions for women, but a reduction to 53%, 63% and 50%, respectively, for men.Conclusions This study identified that markers of impaired function in a range of organs account for a substantial proportion of the apparent effect of age on disease and hospital admissions. It supports a broader, multi-system approach to research and prevention of diseases of ageing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by grants to University of Oxford from the UK Medical Research Council through its funding of the MRC Population Health Research Unit (MRC_MC_U137686853) and the British Heart Foundation. MSC was funded by the Nuffield Department of Population Health. MA was funded by a British Heart Foundation Programme Grant (RG/18/13/33946). RP was funded by the NIHR Oxford Biomedical Research Centre Program, the NIHR Collaboration for Leadership in Health Research and Care (CLARHC) Oxford, the NIHR Program for Applied Research, the NIHR Health Protection Research Unit Gastrointestinal Infections Group and the NIHR Diagnostic Evidence Co-operative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe underlying data is open access through application to the UK Biobank, and materials and methods will be made freely available through the UK Biobank as part of this project.